PKDCC Double Nickase Plasmid (h): sc-410480-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PKDCC Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PKDCC Double Nickase Plasmid (h) and PKDCC Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PKDCC. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PKDCC Antibody (G-10): sc-514504
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PKDCC Double Nickase Plasmid (h) | sc-410480-NIC | 20 µg | $410.00 | |||
PKDCC Double Nickase Plasmid (h2) | sc-410480-NIC-2 | 20 µg | $410.00 |
PKDCC (protein kinase domain containing, cytoplasmic) encodes an atypical serine/threonine kinase often referred to as VLK/PKDCC that localizes to the secretory pathway and contributes to phosphorylation of extracellular and matrix-associated proteins. Through regulation of protein secretion and post-translational modification, PKDCC influences cell–matrix interactions, tissue morphogenesis, and signaling programs linked to development and differentiation. Genetic and expression studies have associated PKDCC with developmental phenotypes and dysregulated extracellular matrix remodeling, supporting its relevance to research on skeletal biology, organogenesis, and disease mechanisms involving altered secretory signaling.
PKDCC Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PKDCC locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PKDCC. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PKDCC function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PKDCC-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.